en · de · es · fr · pt
cardarine-notes.peptides4800.com › News › Preclinical Findings And Safety Signals — Explained

Preclinical Findings And Safety Signals — Explained

By Editorial Desk · published 2025-07-04 · last reviewed 2025-08-22 · News

A practical reference on carcinogenicity: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-08-22 and is reviewed periodically as new material appears.

Preclinical Findings and Safety Signals

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Background and Regulatory Status

Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.

Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.

Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.

Cardarine at a glance

PropertyValueNotes
Primary targetPPARδ (NR1C2)Nuclear receptor involved in lipid metabolism
Preclinical effectIncreased fatty acid oxidationObserved in rodent studies
Key safety signalTumors in rodents after long-term exposureContributed to halted clinical development
Human trial statusNo approved product; development stoppedLimited short-term metabolic data
Sport regulatory statusProhibited at all timesWADA hormone and metabolic modulators class

Mechanism and Research Context

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

Related pages on this site

Identity and Pharmacological Classification

Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Further detail

chemistry The scientific discipline that studies chemical substances, compounds, and molecules composed of atoms of various chemical elements, as well as their compositions, structures, properties, behaviors, and the changes they undergo during reactions with other substances.

For services to the community in Riseley, Bedfordshire. Christine Mary Gendall. For services to the community in Penzance, Cornwall. Terence Brian Gerry. For services to the community in Plymouth, Devon. Beth Laura Gevell. Co-Founder and Director, Arts for Life Project (UK). For services to Young People and to Charity. Amanda Elizabeth Giddins. Chair, Giddo's Gift. For voluntary and charitable services to Young People with Cancer. Kenneth Matthew Gillespie. For services to Young People through Scouting. James Bruce Gillett. For services to the community in Charvil and Reading, Berkshire. Janet Elizabeth Gloin. Manager and Coach, Women's Football, Orpington Football Club. For services to Association Football and to the community in the London Borough of Bromley. Geoffery Frederick Bewick Goldsbrough. Founder, Perennials Charity Rugby Club. For services to Charity in Northern Ireland. Sarah Louise Goodall. Watch Manager, West Yorkshire Fire and Rescue Service. For services to Fire and Rescue. Susan Joy Graham. Chair, Age UK Milton Keynes. For services to Older People in Milton Keynes and Buckinghamshire. Marc Anthony Grayston. Chief Instructor, Maru Karate Kai. For services to Disadvantaged Young People and to the community in Basildon, Essex. Beverley Michelle Greenwood. For services to the community in Glenfield, Leicestershire during Covid-19. Rachael Greenwood. For services to the community in Bramdean and Hinton Ampner, Hampshire. Richard Gregory. For services to the community in Basildon, Essex. Harbaksh Singh Grewal. Vice Chair, UK Punjab Heritage Association.

=== In the United States of America === Clinical pathologists work in close collaboration with clinical scientists (clinical biochemists, clinical microbiologists, etc.), medical technologists, hospital administrators, and referring physicians to ensure the accuracy and optimal utilization of laboratory testing. Clinical pathology is one of the two major divisions of pathology, the other being anatomical pathology. Often, pathologists practice both anatomical and clinical pathology, a combination sometimes known as general pathology. Similar specialties exist in veterinary pathology. Clinical pathology is itself divided into subspecialties, the main ones being clinical chemistry, clinical hematology/blood banking, hematopathology and clinical microbiology and emerging subspecialties such as molecular diagnostics and proteomics. Many areas of clinical pathology overlap with anatomic pathology. Both can serve as medical directors of CLIA certified laboratories. Under the CLIA law, only the US Department of Health and Human Services approved Board Certified Ph.D., DSc, or MD and DO can perform the duties of a Medical or Clinical Laboratory Director. This overlap includes immunoassays, flow cytometry, microbiology and cytogenetics and any assay done on tissue. Overlap between anatomic and clinical pathology is expanding to molecular diagnostics and proteomics as we move towards making the best use of new technologies for personalized medicine.

Sources: en.wikipedia.org

Supporting material

Avoiding smoking Cutting down on fats to help reduce the amount of plaque buildup Eating a healthy diet, including plenty of fruits and vegetables Limiting sodium in the diet, thereby reducing blood pressure Exercising regularly Moderating intake of alcohol, stimulants, sympathomimetics, etc. Maintaining a healthy weight In addition, it is important to control any underlying medical conditions that may increase the risk of stroke or TIA, including:

== Function == LRP1 is a member of the LDLR family and ubiquitously expressed in multiple tissues, though it is most abundant in vascular smooth muscle cells (SMCs), hepatocytes, and neurons. LRP1 plays a key role in intracellular signaling and endocytosis, which implicates it in many cellular and biological processes, including lipid and lipoprotein metabolism, protease degradation, platelet derived growth factor receptor regulation, integrin maturation and recycling, regulation of vascular tone, regulation of blood brain barrier permeability, cell growth, cell migration, inflammation, and apoptosis, as well as diseases such as neurodegenerative diseases, atherosclerosis, and cancer. To elaborate, LRP1 mainly contributes to regulate protein activity by binding target proteins as a co-receptor, in conjunction with integral membrane proteins or adaptor proteins like uPA, to the lysosome for degradation. In lipoprotein metabolism, the interaction between LRP1 and APOE stimulates a signaling pathway that leads to elevated intracellular cAMP levels, increased protein kinase A activity, inhibited SMC migration, and ultimately, protection against vascular disease. While membrane-bound LRP1 performs endocytic clearance of proteases and inhibitors, proteolytic cleavage of its ectodomain allows the free LRP1 to compete with the membrane-bound form and prevent their clearance. Several sheddases have been implicated in the proteolytic cleavage of LRP1 such as ADAM10, ADAM12, ADAM17 and MT1-MMP.

Messenger RNA (mRNA)—template for the synthesis of proteins by ribosomes. Non-coding RNA or "RNA genes"—a broad class of genes that encode RNA that is not translated into protein. The most prominent examples of RNA genes are transfer RNA (tRNA) and ribosomal RNA (rRNA), both of which are involved in the process of translation. However, since the late 1990s, many new RNA genes have been found, and thus RNA genes may play a much more significant role than previously thought. Transfer RNA (tRNA)—transfers specific amino acids to growing polypeptide chains at the ribosomal site of protein synthesis during translation Ribosomal RNA (rRNA)—a component of ribosomes Micro RNA—regulates gene activity Catalytic RNA (Ribozyme)—enzymatically active RNA molecules RNAP accomplishes de novo synthesis. It is able to do this because specific interactions with the initiating nucleotide hold RNAP rigidly in place, facilitating chemical attack on the incoming nucleotide. Such specific interactions explain why RNAP prefers to start transcripts with ATP (followed by GTP, UTP, and then CTP). In contrast to DNA polymerase, RNAP includes helicase activity, therefore no separate enzyme is needed to unwind DNA.

=== Primary === Raynaud's disease, or primary Raynaud's, is diagnosed if the symptoms are idiopathic, that is, if they occur by themselves and not in association with other diseases. Some refer to primary Raynaud's disease as "being allergic to coldness". It often develops in young women in their teens and early adulthood. Primary Raynaud's is thought to be at least partly hereditary. In a large genetic study two genes were identified that predispose for the condition: ADRA2A (alpha-2A-adrenergic receptor for adrenaline) and the transcription factor IRX1. Smoking increases the frequency and intensity of attacks, and a hormonal component exists. Caffeine, estrogen, and nonselective beta-blockers are often listed as aggravating factors, but evidence that they should be avoided is not solid.

Sources: en.wikipedia.org

Notes from published material

By the summer of 1969 it was decided that a full band would be formed and David Nelson was recruited to play lead guitar. In addition to Nelson, Dawson (on acoustic guitar), and Garcia (continuing to play pedal steel), the original line-up of the band that came to be known as the New Riders of the Purple Sage (a nod to the Foy Willing-led Western swing combo from the 1940s, Riders of the Purple Sage, which borrowed its name from the Zane Grey novel) consisted of Alembic Studio engineer Bob Matthews on electric bass and Mickey Hart of the Grateful Dead on drums; bassist Phil Lesh also played sporadically with the ensemble in lieu of Matthews through the end of the year, as documented by the late 1969 demos later included on the Before Time Began archival release. Lyricist Robert Hunter briefly rehearsed with the band on bass in early 1970 before the permanent hiring of Torbert in April of that year. The most commercially successful configuration of the New Riders would come to encompass Dawson, Nelson, Torbert, Spencer Dryden, and Buddy Cage.

=== Naming === Paracetamol is the Australian Approved Name and the British Approved Name as well as the international nonproprietary name that is used by the World Health Organization (WHO); acetaminophen is the United States Adopted Name and the Canadian and Japanese Accepted Name. Both paracetamol and acetaminophen are contractions of chemical names for the compound. The word paracetamol is a shortened form of para-acetylaminophenol, and was coined by Frederick Stearns & Co in 1956, while the word acetaminophen is a shortened form of N-acetyl-p-aminophenol (APAP), which was coined and first marketed by McNeil Laboratories in 1955. The initialism APAP is used by dispensing pharmacists in the United States.

Years pass and Annie contacts Demon about publishing his book. Demon knows that she is expecting a baby and drives to Lee County to meet her instead. After seeing that Lewis has taken Annie to the hospital to give birth, Demon visits Betsy, Dick and June. Skipping a retirement party for Coach, Demon fears the traumatic memories that returning to Lee County would surface. He asks Betsy about Angus’ love life, knowing she shares things with Betsy she doesn’t with him. Coyly, the old woman tells him to ask her himself, saying she only has one man in mind. Visiting Angus the next day, who is preparing to sell Coach's old house, Demon begins to understand they have always had feelings for each other. The book ends with Angus and Demon driving toward the ocean together, his hand tenderly touching the back of her neck.

Sources: en.wikipedia.org

Frequently asked questions

What did animal studies show?

Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.

Has cardarine been tested in humans?

Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.

Does cardarine improve athletic performance in people?

Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.

Is cardarine approved for human use?

No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.

Network